In another study, participants were given a drug called leronlimab, which increased cell surface CCR5 levels and led to related symptom improvement.
https://t.co/U5jKqeHUbH
River couldn't find a home for the holidays 😔. He is a playful, spunky and full of energy! How handsome is he!? If you could share this post so we could find River a home, that would be wonderful. Let's find this boy a home!
Learn more about River here:
https://t.co/8iQV2X3o73
The expected features of v1 HUMBL Platform:
1. Connected wallets
2. Verified profiles
3. Search engine
4. Marketplace
(Tickets, NFTs, etc.)
We will be doing a #HUMBL Social closed-loop 500 person beta to pace content, moderation, etc. and will take signups next week.
@WynnWs If I’m not mistaken, Leronlimab helped you? Waiting for the drug to be approved so it can help others. It’s on the way. So glad you’re recovered!!
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical #COVID19#SARSCoV2
https://t.co/gdKmLZQ84v
"treatment with the CCR5 blocking antibody leronlimab, ... restoration of the CD4/CD8 ratio"
Led by Dr. Otto Yang, a @dgsomUCLA-led team of researchers studying the effect of the monoclonal antibody #Leronlimab on #LongCOVID may have found a surprising clue to the baffling syndrome. 🔬
@UCLAHealth 📰: https://t.co/4zSXrONx8a
@OxfordJournals 📝: https://t.co/hVsRUDb9jv
"These findings suggest an unexpected alternative mechanism for #LongCovid. Rather than persistent immune activation, we observed abnormal immune downmodulation, which is normalized by leronlimab [a CCR5 antibody]"
https://t.co/wTQI7bYmDg